
Company Performance - Innospec reported quarterly earnings of $1.26 per share, exceeding the Zacks Consensus Estimate of $1.17 per share, but down from $1.39 per share a year ago, representing an earnings surprise of +7.69% [1] - The company posted revenues of $439.7 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 1.78% and showing a slight increase from $435 million year-over-year [2] - Over the last four quarters, Innospec has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times [2] Stock Performance and Outlook - Innospec shares have declined approximately 27.9% since the beginning of the year, contrasting with the S&P 500's gain of 7.6% [3] - The current consensus EPS estimate for the upcoming quarter is $1.28 on revenues of $452.1 million, and for the current fiscal year, it is $5.47 on revenues of $1.82 billion [7] Industry Context - The Chemical - Diversified industry, to which Innospec belongs, is currently ranked in the bottom 7% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Innospec's stock performance [5]